Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Altay Therapeutics STAT3 inhibitor
- Development stage
- Preclinical
- Lead developer
- Altay Therapeutics
- Modality
- Small Molecules
- Administration
- Oral, Intraperitoneal, Subcutaneous, Intravenous, Intramuscular, Intraarterial, Transdermal
01
Overview
Altay Therapeutics is developing a small molecule STAT3 inhibitor for the treatment of cancer and inflammatory diseases. STAT3 (signal transducer and activator of transcription 3) is a transcription factor that, when activated, promotes immune dysregulation, fibrosis, and oncogenesis. Altay's inhibitor is designed to bind directly to the activated form of STAT3, demonstrating nanomolar potency while maintaining high selectivity to avoid inhibiting the closely related STAT1 protein. This selectivity is intended to minimize off-target effects and toxicity. The program is currently in preclinical development, with potential applications in systemic sclerosis-associated interstitial lung disease (SSc-ILD), ovarian cancer, and various fibrotic and autoimmune conditions such as rheumatoid arthritis and ulcerative colitis.
- Other names
- STAT3 inhibitorSTAT-3 inhibitorSTAT 3 inhibitor
02
Targets
STAT3 (Signal Transducer and Activator of Transcription 3)
Beyond the preview
Go deeper on Altay Therapeutics STAT3 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Altay Therapeutics STAT3 inhibitor.